Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma

K. Eger (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands)

Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes

Session: Severe asthma phenotypes and outcomes
Session type: Oral Presentation
Number: 5041

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Eger (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands). Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma. 5041

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.